Opportunities of application of short regimens for MDR-TBat the expense of using intravenous administration of anti-TB drugs during intensive phase Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Intrapulmonary drug administration in neonatal and paediatric critical care: a comprehensive review Source: Eur Respir J 2011; 37: 678-689 Year: 2011
Rational use of anti-tuberculosis drugs in the EU: better patient care and less drug resistance Source: Eur Respir J 2012; 39: 802-804 Year: 2012
Dose optimisation of first-line tuberculosis drugs using therapeutic drug monitoring in saliva: feasible for rifampicin, not for isoniazid Source: Eur Respir J, 56 (4) 2000803; 10.1183/13993003.00803-2020 Year: 2020
Potential economic savings of administration of home intravenous antibiotic therapy to patients with acute respiratory infections in Ireland Source: Annual Congress 2011 - The impact of the organisation of care on costs: the role of the physician in home care Year: 2011
An audit of adherence to antituberculous drugs using a new, rapid, point of care test for isoniazid metabolites Source: Eur Respir J 2002; 20: Suppl. 38, 566s Year: 2002
Physical therapy continuous monitoring in ICU in a large public hospital: an effective strategy to optimize the weaning process in critical patients Source: Annual Congress 2007 - Critical care and airways clearance Year: 2007
Therapeutic drug monitoring practice in patients with active tuberculosis: assessment of opportunities Source: Eur Respir J, 57 (1) 2002349; 10.1183/13993003.02349-2020 Year: 2021
The efficacy, safety and tolerability of the short 12-month MDR-TB regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Treatment of multi-drug-resistant tuberculosis (MDRTB): where are we now? Year: 2017
Integrated care pathways significantly reduce drug dosing and administration errors in patients with acute asthma Source: Eur Respir J 2006; 28: Suppl. 50, 481s Year: 2006
The efficacy, safety and tolerability of the short 12-month pre-XDR-TB regimen regimen in Ukraine at the expense of using intravenous administration of anti-tuberculosis drugs during intensive phase Source: International Congress 2017 – Paediatric TB: MDRTB (II) Year: 2017
Update on novel anticoagulants: indications, dosing alternatives and outcomes Source: International Congress 2018 – Pulmonary embolism: what we need to know Year: 2018
Practical treatment of community acquired pneumonia (CAP) with outpatient parenteral antibiotic therapy (OPAT) and switch therapy: CTRX and LVFX Source: Annual Congress 2008 - Diagnostic tests in lower respiratory tract infections Year: 2008
Therapeutic drug monitoring using saliva as matrix: an opportunity for linezolid, but challenge for moxifloxacin Source: Eur Respir J, 55 (5) 1901903; 10.1183/13993003.01903-2019 Year: 2020
Interrelationship of pharmacokinetics/pharmacodynamics: antibiotic dosing for the future Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=1 Year: 2004
Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children Source: Eur Respir J, 57 (1) 2001756; 10.1183/13993003.01756-2020 Year: 2021
The effect of educational interventions of administering the first dose of antibiotics within 4 hours on community acquired pneumonia management Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008
Clinical management: recommended practice including the place of antibiotics Source: Annual Congress 2007 - PG24 - GRACE full-day course. From cough to asthma: the role of infection Year: 2007
The frequency of prescribing antimicrobial drugs in the initial therapy of COVID-19 at the outpatient stage Source: Virtual Congress 2021 – COVID - 19 treatments Year: 2021